scholarly article | Q13442814 |
P50 | author | Toshihiko Doi | Q80212852 |
Narikazu Boku | Q88572199 | ||
Atsushi Ohtsu | Q115365827 | ||
P2093 | author name string | Manabu Muto | |
Shigeaki Yoshida | |||
Tomonori Yano | |||
Yasuo Hamamoto | |||
Hiroki Kawai | |||
Yasushi Sano | |||
Fumio Nagashima | |||
Kiyomi Mera | |||
P2860 | cites work | Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer | Q28361226 |
Late phase II study of S-1 in patients with advanced head and neck cancer | Q33339533 | ||
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials | Q34620968 | ||
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group | Q36621749 | ||
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | Q40613157 | ||
Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice | Q43835909 | ||
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study | Q43887008 | ||
Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. | Q53667890 | ||
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators | Q71665880 | ||
Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group | Q73676552 | ||
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients | Q77809280 | ||
P304 | page(s) | 19-23 | |
P577 | publication date | 2003-01-01 | |
P1433 | published in | Gastric Cancer | Q15724608 |
P1476 | title | Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey | |
P478 | volume | 6 Suppl 1 |
Q37042302 | Advanced gastric cancer showing long-term complete remission in response to S-1 monotherapy: two case reports |
Q98288637 | Clinical Complete Response after Chemotherapy and Palliative Surgery for Unresectable Gastric Cancer |
Q83969769 | Histological complete response in advanced gastric cancer after 2 weeks of S-1 administration as neoadjuvant chemotherapy |
Q41907282 | S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. |
Q36403318 | Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer. |
Search more.